Summary
Samsung Biologics has spent more than a decade proving that large-scale biologics manufacturing can generate exceptional economics when capacity is paired with high utilization and disciplined execution.
That model is now entering a more complex phase.
On October 2, the company disclosed a KRW 93.48 billion manufacturing agreement with an undisclosed European pharmaceutical company, running through the end of 2031. The contract represents 2.05% of 2025 revenue and follows a larger KRW 350.77 billion European manufacturing agreement disclosed in September.
The individual order is not the main investment event.
Samsung Biologics is simultaneously ramping Plant 5, operating its first U.S. manufacturing site in Rockville, pursuing the CHF 1.46 billion acquisition of peptide CDMO PolyPeptide and issuing new equity to finance that transaction.
The strategic direction is clear: Samsung Biologics is moving from a Korea-centered, antibody-heavy manufacturing model toward a broader global CDMO platform spanning more geographies and modalities.
The investment question is whether that expansion can produce the same quality of returns as the business it is expanding from.
Key Takeaways
- ✓ The latest KRW 93.48 billion European contract reinforces order momentum, but its value will be recognized over a multi-year period through 2031. It should not be treated as near-term revenue.
- ✓ Samsung Biologics now has 845,000 liters of global biologics capacity, including the 180,000-liter Plant 5 and the 60,000-liter Rockville site in Maryland.
- ✓ The proposed PolyPeptide acquisition would add peptide API capabilities and significant exposure to metabolic therapeutics. PolyPeptide’s H1 2026 revenue rose 41.6% and EBITDA margin improved to 20.7%, strengthening the industrial logic of the transaction.
- ✓ The central investment question is moving from capacity expansion to capital efficiency: Plant 5 utilization, Rockville commercialization, PolyPeptide integration and margin preservation now matter more than headline capacity alone.
What Happened
Samsung Biologics signed a KRW 93.48 billion contract manufacturing agreement with an undisclosed European pharmaceutical company on October 2.
The contract begins immediately and runs through December 31, 2031. Its value is equivalent to 2.05% of Samsung Biologics’ 2025 revenue.
That percentage needs context.
The KRW 93.48 billion is the total disclosed contract value across a multi-year manufacturing period, not revenue that will be recognized in 2026.
The agreement follows another European pharmaceutical manufacturing contract announced in September worth KRW 350.77 billion, with a contract period extending through 2033. Together, the disclosures show that long-duration order activity remains intact.
But contract flow is only one part of what is changing at Samsung Biologics.
Plant 5, which added 180,000 liters of capacity in Songdo, is now operational and progressing through process performance qualification and commercial ramp-up. The company’s existing Plants 1 through 4 continued stable operations in the second quarter.
In March, Samsung Biologics also completed the acquisition of GSK’s Rockville, Maryland manufacturing site. The facility has two cGMP manufacturing plants with a combined 60,000 liters of drug-substance capacity and marks the company’s first manufacturing presence in the United States.
That brought global manufacturing capacity to 845,000 liters.
The next expansion is not another antibody plant.
Samsung Biologics is currently conducting a public tender offer for Switzerland-based PolyPeptide Group at CHF 44.31 per share, implying an equity value of approximately CHF 1.46 billion.
The main tender period runs through October 12. PolyPeptide’s largest shareholder, representing approximately 55.65% of outstanding shares excluding treasury shares, has committed to tender its stake. Completion remains subject to the tender conditions and regulatory approvals.
The acquisition has therefore not yet closed.
At the same time, Samsung Biologics is raising new equity to finance the transaction.
Following the October 1 adjustment, the first issue price for 2.27 million new shares was set at KRW 1.174 million per share, reducing the indicated gross proceeds to approximately KRW 2.665 trillion.
The final issue price has not yet been determined.
This combination — new contracts, new capacity, a U.S. manufacturing footprint, a pending peptide acquisition and fresh equity financing — makes the current investment question much larger than the latest order.
Why It Matters
Samsung Biologics’ original growth model was unusually simple.
Build standardized large-scale biologics capacity.
Win global pharmaceutical programs.
Qualify production lines.
Increase utilization.
Convert a high fixed-cost asset base into revenue and operating leverage.
That model worked.
On the company’s post-spin-off CDMO reporting basis, revenue increased from KRW 3.497 trillion in 2024 to KRW 4.557 trillion in 2025.
Operating profit increased from KRW 1.321 trillion to KRW 2.069 trillion.
Operating margin expanded from 37.8% to 45.4%.
The economic engine was not capacity alone.
It was capacity combined with utilization.
That distinction becomes more important as Samsung Biologics enters its next phase.
Plant 5 expands the existing model.
Rockville expands the geography.
PolyPeptide would expand the modality.
Those are three different types of growth, with three different execution requirements.
A new Songdo plant can benefit from an operating model Samsung has already repeated several times. A U.S. facility must prove that Samsung can transfer that execution discipline across geography. A peptide acquisition must prove that Samsung can create value in a manufacturing platform with different processes, customers and economics.
Growth is therefore becoming less about how many liters Samsung Biologics can build.
It is becoming more about how efficiently the company can deploy capital across a broader manufacturing network.
The latest European contract is confirmation, not the thesis.
The more important development is the transition from a scale-led biologics manufacturer into a multi-region, multi-modality CDMO.
That transition can strengthen Samsung Biologics.
Customers increasingly care about more than raw production capacity. Geographic supply resilience, multiple manufacturing locations, specialized modalities and the ability to support a molecule from development through commercial production can all influence outsourcing decisions.
Rockville addresses geography.
PolyPeptide addresses modality.
Plant 5 preserves the scale advantage.
Together, they create a stronger strategic platform.
But they also change the burden of proof.
Samsung Biologics has already demonstrated that it can build large plants and fill them.
The company has not yet demonstrated at the same scale that it can acquire a specialized foreign manufacturing network, improve its economics and connect that platform to existing global clients.
PolyPeptide’s recent results make that question more nuanced than a simple margin-dilution argument.
PolyPeptide generated EUR 236.6 million of revenue in H1 2026, up 41.6% year over year. EBITDA reached EUR 49.1 million and EBITDA margin improved to 20.7%, from just 2.7% a year earlier.
Growth was led by metabolic therapeutics, which accounted for 68.4% of first-half revenue.
That means Samsung is not attempting to buy a stagnant asset.
It is attempting to buy into an already accelerating peptide manufacturing cycle.
The question is whether Samsung can make that growth more valuable.
For investors, the proof will not be acquisition completion itself.
It will be customer cross-selling, utilization, margin progression and ultimately return on the capital committed to the transaction.